Moreover, our study provided a new insight into molecular mechanisms whereby the HDAC inhibitor TSA repressed IRF5 expression, and suggested a mechanistic rationale for application of HDACi in the treatment of autoimmune diseases such as SLE. This evidence concerns the gene IRF5 and autoimmune disease.